title: Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes.
abstract: This is a unifying theory that cholesterol metabolites (isoprenoids) are an integral component of the signaling pathway for interleukin-6 (IL-6) mediated inflammation. IL-6 inflammation is the common causative origin for atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, dementia, Alzheimer's disease and type 2 diabetes. Therapeutic effects of bisphosphonates and statins are mediated by isoprenoid depletion. Statins and bisphosphonates act in the cholesterol pathway to deplete isoprenoids. Anti-inflammatory properties of statins and bisphosphonates are due to isoprenoid depletion with subsequent inhibition of IL-6 mediated inflammation. Therapeutic targets for the prevention and control of all the above diseases should focus on cholesterol metabolites and IL-6 mediated inflammation. Prevention of atherosclerotic vascular disease and age-related disorders will be by utilization of cholesterol lowering agents or techniques and/or treatment with statins and/or bisphosphonates to inhibit IL-6 inflammation through regulation of cholesterol metabolism.
authors.affiliation: Division of Inflammation and Pain Research, L.A. Pain Clinic, 4019 W. Rosecrans Avenue, Hawthorne, CA 90250, USA. medicinechief@aol.com
authors.forename: Sota
authors.initials: S
authors.lastname: Omoigui
mesh_terms: D000375:Aging / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001161:Arteriosclerosis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002784:Cholesterol / Q000009:adverse effects / Q000096:biosynthesis*; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology*; D015850:Interleukin-6 / Q000502:physiology*; D010024:Osteoporosis / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy
chemical_list: D018836:Inflammation Mediators; D015850:Interleukin-6; D002784:Cholesterol